key: cord-0998107-ax8trira
authors: Smith, Deane E.; Chang, Stephanie H.; Geraci, Travis C.; James, Les; Kon, Zachary N.; Carillo, Julius A.; Alimi, Marjan; Williams, David; Scheinerman, Joshua A.; Cerfolio, Robert J.; Grossi, Eugene A.; Moazami, Nader; Galloway, Aubrey C.
title: One-Year Outcomes With Venovenous Extracorporeal Membrane Oxygenation Support for Severe COVID-19
date: 2022-03-10
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2022.01.003
sha: 9e328c1647f108e1b287c1324e42bd73807fd5e5
doc_id: 998107
cord_uid: ax8trira

BACKGROUND: Severe coronavirus disease 2019 (COVID-19) can cause acute respiratory failure requiring mechanical ventilation. Venovenous (VV) extracorporeal membrane oxygenation (ECMO) has been used in patients in whom conventional mechanical ventilatory support has failed. To date, published data have focused on survival from ECMO and survival to discharge. In addition to survival to discharge, this study reports 1-year follow-up data for patients who were successfully discharged from the hospital. METHODS: A single-institution, retrospective review of all patients with severe COVID-19 who were cannulated for VV-ECMO between March 10, 2020 and May 1, 2020 was performed. A multidisciplinary ECMO team evaluated, selected, and managed patients with ECMO support. The primary outcome of this study was survival to discharge. Available 1-year follow-up data are also reported. RESULTS: A total of 30 patients were supported with VV-ECMO, and 27 patients (90%) survived to discharge. All patients were discharged home or to acute rehabilitation on room air, except for 1 patient (3.7%), who required supplemental oxygen therapy. At a median follow-up of 10.8 months (interquartile range [IQR], 8.9-14.4 months) since ECMO cannulation, survival was 86.7%, including 1 patient who underwent lung transplantation. Of the patients discharged from the hospital, 44.4% (12/27) had pulmonary function testing, with a median percent predicted forced expiratory volume of 100% (IQR, 91%-110%). For survivors, a 6-minute walk test was performed in 59.3% (16/27), with a median value of 350 m (IQR, 286-379 m). CONCLUSIONS: A well-defined patient selection and management strategy of VV-ECMO support in patients with severe COVID-19 resulted in exceptional survival to discharge that was sustained at 1-year after ECMO cannulation.

non-COVID ARDS. [4] [5] [6] Despite this, when the pandemic reached New York City in March 2020, we offered VV-ECMO to patients with severe COVID-19 who met specific inclusion criteria (Supplemental Text). Since the initial surge of the pandemic, a growing body of literature has emerged reporting outcomes of patients cannulated for ECMO for COVID-19. [7] [8] [9] [10] [11] To date, nearly all reports have focused on the standard ECMO outcome metrics of survival from ECMO and survival to hospital discharge. Although these are important markers for reporting standards, they are inherently limited in scope because they do not reflect overall clinical recovery.

Given the lack of posthospitalization outcomes of patients who underwent VV-ECMO support for severe COVID-19, we report the final disposition status for all 30 patients from our initial experience, as well as 1year outcomes.

A single-institution (NYU Langone Health, New York, NY) retrospective review of all patients with severe COVID-19 who were supported with VV-ECMO between March 10, 2020 and May 1, 2020 was performed. A multidisciplinary team evaluated patients for ECMO cannulation on the basis of the development of ARDS secondary to COVID-19, underlying comorbidities, and a determination of reasonable likelihood for survival with ECMO support. 9 The primary outcome was survival to discharge. Hospital and ECMO-related complications were also reported. As a secondary outcome, survival and clinical status at 1 year after ECMO cannulation were evaluated. This study was approved by the Institutional Review Board at NYU Langone Health (IRB #S20-00611), and a waiver of informed consent was obtained.

PATIENT SELECTION AND MANAGEMENT. The diagnosis of COVID-19 was established by nasal pharyngeal swab for reverse transcriptase polymerase chain reaction assay.

Patients were evaluated, cannulated for VV-ECMO, and managed by a multidisciplinary team of cardiothoracic surgeons and critical care physicians. 9 patient was admitted for respiratory support requiring intermittent ventilation through a tracheostomy.

Notably, the patient who was admitted for respiratory support was the same patient who was discharged with daily supplemental oxygen therapy. One patient died after discharge from the hospital as a result of end-stage liver disease and was awaiting liver transplantation at the time of death. In-hospital clinical outcomes are summarized in Table 3 . 

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in coronavirus disease 2019: experience with 32 patients

Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Extracorporeal membrane oxygenation support in severe COVID-19

Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure

Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): multicenter experience of referral hospitals in a large health care system

Evaluation of anti-Xa and activated partial thromboplastin time monitoring of heparin in adult patients receiving extracorporeal membrane oxygenation support

Novel percutaneous tracheostomy for critically ill patients with COVID-19

Lobectomy for hemorrhagic lobar infarction in a patient with COVID-19

The authors would like to acknowledge Dr Georgeann McGuinness, Dr William Moore, and Dr Jane Ko for their expertise in the interpretation of radiographic studies for this patient cohort. The authors would also like to acknowledge the NYU Langone Health ECMO and perfusion team and the physicians, advanced practice providers, nurses, and hospital staff who contributed to the care of these patients during the height of the pandemic.